

**STATE BOARD OF OPTOMETRY**

2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course
Approval Checklist

Title:

Provider Name:

☒ Completed Application

Open to all Optometrists? ☒ Yes ☐ No

Maintain Record Agreement? ☒ Yes ☐ No

☒ Correct Application Fee

☒ Detailed Course Summary

☒ Detailed Course Outline

☐ PowerPoint and/or other Presentation Materials **Not applicable to this course - explanation included**

☒ Advertising (optional)

☒ CV for EACH Course Instructor

☒ License Verification for Each Course Instructor

Disciplinary History? ☐ Yes ☒ No



STATE BOARD OF OPTOMETRY
2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL APPLICATION

\$50 Mandatory Fee

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.

Course Title <u>Practical Solutions to Common Retinal Problems</u>	Course Presentation Date <u>10/13/2016</u>
---	---

Course Provider Contact Information

Provider Name			
<u>Leslie</u> (First)	<u>Kuhlman</u> (Last)	<u>Ann</u> (Middle)	
Provider Mailing Address			
Street <u>75 Enterprise</u>	City <u>Aliso Viejo</u>	State <u>CA</u>	Zip <u>92673</u>
Provider Email Address <u>Leslie.Kuhlman@nvisioncenters.com</u>			
Will the proposed course be open to all California licensed optometrists?			<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?			<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

Course Instructor Information

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

Instructor Name			
<u>Ron</u> (First)	<u>Gallimore</u> (Last)	<u>P.</u> (Middle)	
License Number <u>678240</u>		License Type <u>MD</u>	
Phone Number <u>310 944 9393</u>		Email Address <u>rongallimoremd@gmail.com</u>	

I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.

[Signature]
Signature of Course Provider

10/1/16
Date



NVISION Eye Centers FREE 4-HOUR CE*

Thursday, October 13, 2016

Crowne Plaza Redondo Beach & Marina Hotel | 300 N. Harbor Dr. | Redondo Beach, CA 90277

CE Speakers Includes: **Franklin Lusby, MD | Ron Gallemore, MD | Amarpreet Brar, MD and more...**

CE Topics: **Refractive Surgery, Retina, Cataract, more details to follow...**

Event Schedule:

Join NVISION Eye Centers and Retina Macula Institute for an exciting evening of continuing education, networking, dinner, libations, and raffles. We are offering four hours of COPE accredited education to regional ODs.

5:00 – 5:30pm Registration

5:30 – 10:00pm CE Program

*Early bird registration ends Sept. 19, 2016
Early bird registrants will receive extra raffle tickets!
Pending California State and COPE Approval*

CE Schedule

Limited Spots | For event updates, Contact **Stephanie Andrews**
E • Stephanie.Andrews@nvisioncenters.com | P • 310.531.3625

redondobeachfree4hrce.eventbrite.com

NVISION
EYE CENTERS



DINNER

VENDOR
BOOTHS



RAFFLES

STATE BOARD OF OPTOMETRY
2450 Del Paso Road, Suite 105
Sacramento, CA 95834

On behalf of NVISION Eye Centers, we are writing to request approval of Continuing Education to California doctors of optometry. The education will be delivered by Board Certified Ophthalmologists, clinical investigators and experts in technology and patient consultation.

We are writing in response to your letter for information pursuant to CCR 1536 (g), to address why our application was submitted earlier than 45 days for course accreditation. As well as additional content requested.

The reason why our application was submitted earlier than 45 days for the course named "Practical Solutions to Common Retinal Problems" given October 13, 2016 was due to the material being in development prior to the time period needed. The presenter was not able to provide the material prior to our submission on October 1, 2016. Once a topic and summary was produced, we moved quickly to process accreditation requests. Please accept our apologies and deepest regrets. Going forward, we will make every effort to process these applications in a timely manner.

Professional Advancement: NVISION Eye Centers seeks to offer professional education to local and regional optometrist. As a leading practice in the ophthalmology field, NVISION doctors are engaged in research and latest developments on procedures, technology, and clinical therapies. The field of optometry is constantly evolving at a rapid pace and optometrists need to keep up. NVISION seeks to help practicing optometrists to understand the new technology that has elevated standard of care, common problems can be associated with uncommon, sight threatening complications, F/up "abnormal" findings, ERM, PVD, early signs of AMD and early signs of DR.

PowerPoint/Presentation Material: This course was given by an external presenter who did not furnish NVISION a copy of his slides, so there are not presentation materials or a PowerPoint. All course content is reflected in the outline.

Program Date: October 13, 2016, and additional dates thereafter.

Location: Crowne Plaza, Redondo Beach

Presenters: Ron Gallemore, MD

Conditions of Availability: This course will be open to all licensed ODs. They will be notified through flyers, Eventbrite, and fax by request.

Records: NVISION Eye Centers to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as required for a minimum of three years.

Program Name and Description: Practical Solutions to Common Retinal Problems

This course will review Epiretinal Membranes, Dry AMD, Wet AMD, HTN retinopathy, Central Serous Retinopathy, Naaion, Diabetic Macular Edema, Retinal Vein Occlusion, Uveitis, Commotio Retinae, PVD, and Vision loss following cataract surgery.

Course Objective: To help practicing optometrists to understand the New technology that has elevated standard of care, Common problems can be associated with uncommon, sight threatening complications, F/up "abnormal" findings, ERM, PVD, early signs of AMD and early signs of DR.

We are seeking a total of 1.5 hour of continuing education credit for these courses. The contact person for this program is myself, and I can be reached at 949.234.8129 or Leslie.Kuhlman@nvisioncenters.com.

Sincerely,

Leslie Kuhlman
NVISION Laser Eye Centers

75 Enterprise, Suite 200, Aliso Viejo, CA 92656

p: 949.274.4652 • **f:** 949.509.4858 • **e:** info@nvisioncenters.com • **w:** www.nvisioncenters.com

October 1, 2016

On behalf of NVISION Eye Centers, we are writing to request approval of Continuing Education to doctors of optometry. The education will be delivered by Board Certified Ophthalmologists, clinical investigators and experts in technology and patient consultation.

Program Date: October 13, 2016, and additional dates thereafter.

Location: Crowne Plaza, Redondo Beach

Conditions of Availability: This course will be open to all licensed ODs. They will be notified through flyers, Eventbrite, and fax by request.

Records: NVISION Eye Centers to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as required for a minimum of three years.

Program Name and Description:

Practical Solutions to Common Retinal Problems

This course will review Epiretinal Membranes, Dry AMD, Wet AMD, HTN retinopathy, Central Serous Retinopathy, Naaion, Diabetic Macular Edema, Retinal Vein Occlusion, Uveitis, Commotio Retinae, PVD, and Vision loss following cataract surgery.

Course Objective:

To help practicing optometrists to understand the New technology that has elevated standard of care, Common problems can be associated with uncommon, sight threatening complications, F/up "abnormal" findings, ERM, , PVD, early signs of AMD and early signs of DR.

We are seeking a total of 1 hour of continuing education credit for these courses. The contact person for this program is myself, and I can be reached at 949.234.8129 or Leslie.Kuhlman@nvisioncenters.com.

Sincerely,

Leslie Kuhlman
NVISION Laser Eye Centers
Continuing Education and Special Projects Coordinator

Presenter – Ron Gallemore, MD, PhD
Founder and Director
Retina Macula Institute and Research Center
Assistant Clinical Professor
Jules Stein Eye Institute
UCLA School of Medicine

Course Title – Practical solutions to common retinal problems

Course Outline –

Epiretinal Membranes

Screen w oct

-may have CME

-associated BRVO

-good va not necessarily good prognosis

Screen with optos/BIO

15% have associated tear

Dry AMD

-latest vitamin guidelines

-role of genetic testing

-home screening options

-implantable miniature telescope

Wet AMD

-Anti-vegf

-current options

-how to choose

-contraindications to anti-vegf

-role of steroids

-role of PDT

HTN retinopathy

Under diagnosed

Life saving diagnosis

-higher rate of CVA, MI

Learn to recognize

Check BP in office

Central Serous Retinopathy

Not a benign self limited condition

Permanent contrast sensitivity loss

Therapeutic options

-drops

-hot laser

- cold laser
 - oral diuretics
 - anti-veg
 - combo therapies
- Stop the hidden steroid
- testosterone
 - Flonase
 - creams for eczema etc.
 - inhalers
 - injection for ortho problems
- Other hidden causes
- stress, sleep, caffeine, other stimulants

Naaion

On the rise

Better screening?

Drug induced-

- meth heads
- steroid induced iop spike
- ED drugs

Counsel high risk patients

Treatment

- drop cocktail
- injections
- BP control
- treat sleep apnea
- asa for pts w cvdz
- control lipids

Diabetic Macular Edema

- screen with photos and oct
- 20/20 va doesn't mean observe
- refer early for best results
- drug induced edema still occurs
- check med list
- dcct and f/up visits - tighter control warrants closer visits

Retinal Vein Occlusion

- seen more often in younger patients
- intense work outs
- bcp
- anabolic steroids
- better screening by General eye docs
- high percentage w clotting disorder, increased morbidity n mortality

Uveitis

- Don't forget differential
- inflammation top of list



- may be associated with systemic disease
- infection
- infiltration: lymphoma is on the rise

Commotio Retinae

Secondary to blunt trauma

Can be associated with long term and late complications

- Mac edema
- Epiretinal membrane
- CNV
- Macular hole

Screen with oct

Look for inflammatory cells

Treat with topical steroids

Refer

- dialysis
- above complications

PVD

Not always benign

Be wary of counseling your patient "normal process of aging"

Death is a normal process of aging too but can be delayed or prevented at a given moment

Appropriate exam

Appropriate f/up

Vision loss following cataract surgery

Largely preventable

Screen with exam and OCT

Prophylaxis against CME

- pre-op NSAID n steroid
- anti-vegf in high risk cases
- stop PGA

--switch to CAI containing drop

Follow high risk patients more closely

- erm
- diabetic even w/o retinopathy
- systemic inflammatory disease
- RA
- Lupus
- inflammatory bowel disease
- back pain

Summary

New technology has elevated standard of care

Common problems can be associated with uncommon, sight threatening complications

F/up "abnormal" findings

- erm
- PVD

VISION

EYE CENTERS

- early signs of AMD
- early signs of DR

Co-manage the higher risk pts

RON P. GALLEMORE, M.D., PH.D.
CURRICULUM VITAE

WORK

Retina Macula Institute
Position: Founder and Director
4201 Torrance Blvd., Ste. 220
Torrance, CA 90503
Phone: (310) 944-9393
Fax: (310) 944-3393
E-mail: rongallemoremd@gmail.com
Website:
www.retinamaculainstitute.com

HOME

1461 9th St
Manhattan Beach CA, 90266
Phone: (310) 413-7020

PERSONAL

Date of Birth: December 18, 1964
Place of Birth: Glendora, CA
Spouse: Esmeralda E. Gallemore
Children: Ron Paul Jr., Giavanni Laurette
Heather, Michael and Amy

EDUCATION

COLLEGE

University of California, Irvine
Irvine, California
B. S. School of Biology
Magna Cum Laude
September 1982 - June 1986

MEDICAL SCHOOL

University of California
San Francisco, CA
M. D., School of Medicine
Ph.D., Neuroscience
September 1986 - May 1992

INTERNSHIP

Mercy Hospital and Medical Center
San Diego, CA

Ron P. Gallemore

Transitional Internship
June 1992 - June 1993

RESIDENCY

Jules Stein Eye Institute
UCLA Medical Center
Los Angeles, CA
Ophthalmology Resident
July 1993 - June 1996

FELLOWSHIP

Duke University Medical Center
Durham, NC
Vitreoretinal Surgery Fellowship
July 1996 - June 1998

BOARD CERTIFICATION

American Board of Ophthalmology

LICENSURE

California - G78240
DEA - BG3932072

PROFESSIONAL BACKGROUND

Retina Vitreous Associates Medical
Group
1127 Wilshire Blvd. Suite 1620
Los Angeles, CA 90017
July 1998-October 2007

Retina Macula Institute
Founder and Director
4201 Torrance Blvd., Suite 220
Torrance CA, 90503
Dec 2007-Present

ACADEMIC POSITIONS

*Clinical Instructor, Jules Stein Eye Institute,
UCLA Clinical Instructor
1998-Present*

*Clinical Instructor, Retina Division,
Duke University Eye Center
1995-1997*

Ron P. Gallemore

Conference Director
Duke Eye Center Fluorescein Angiography
1996-1997

Lecturer, Program in Biological Sciences
University of California, San Francisco
1990-1992

Teaching Assistant
Neuroanatomy, School of Medicine
University of California, San Francisco
1990

Teaching Assistant and Course Tutor
Physiology, Biochemistry, General Chemistry,
Organic Chemistry, Developmental and Cell
Biology, Psychobiology, and Sensory
Physiology. Dept. of Biological Sciences
University of California, Irvine
1983-1986

Review Course Instructor and Organizer
"Catching Carbon Chemistry" and "Intro to
General Chemistry"
University of California, Irvine

AWARDS AND HONORS

2012 – Academy of Ophthalmology – Lifetime Achievement Award

2011 – Super Doctors Los Angeles – Southbay's Top Doctors Award

2000 – Jules Stein Eye Institute Alumni Research Award

1999 – Jules Stein Eye Institute Alumni Research Award

1997 - Ronald G. Michels Fellowship Foundation Award

1997 - Heed/Knapp Fellowship, Heed Ophthalmic Foundation

1996 - Heed Fellowship, Heed Ophthalmic Foundation

Ron P. Gallemore

1996 - Society of Heed Fellows Fellow, Heed Ophthalmic Foundation

1996 - Jules Stein Eye Institute Laboratory Research Award

1995 - Schepens International Society, Outstanding Research Paper Award, Mexico City

1995 - Jules Stein Eye Institute Laboratory Research Award

1995 - Jules Stein Eye Institute Resident Research Award

1994 - Dr. Henry and Lilian Nesburn Research Award Los Angeles Society of Ophthalmology

1993 - Robert J. Prentiss Original Research Award Mercy Hospital, San Diego, CA

1989, 1990 - National Eye Institute Research Service Award

1986 - Dean's Summer Research Fellowship University of California, San Francisco

1985 - Fight for Sight Student Fellowship

1985 - Dr. W. F. Holcomb Research Scholar Award University of California, Irvine

1985 - Dean's Academic Achievement and Service Award - University of California, Irvine

1984 - Phi Beta Kappa - Liberal Scholarship

1984 - Robert Ernst Prize for Excellence in Research in the Biological Sciences

1984 - Alpha Epsilon Delta Honor Society, University of California, Irvine

1984 - Swedish Club of Los Angeles Inc. Academic Scholarship Award

1983, 1984 - Chancellor's Scholar, U.C. Irvine

Ron P. Gallemore

1983 - Phi Beta Kappa Honor Society (Sophomore)

1983, 1984 - President's Undergraduate Research Grant U.C. Irvine

1983, 1984 - Excellence in Research Award UC Irvine

1983 - Committee for Undergraduate Development Research Scholarship - U.C. Irvine

1982 - Excellence in Research Award Southern California Academy of Sciences

1982 - Scholarship for Academic Excellence and Community Service, RCU #324

ACTIVE CLINICAL TRIALSPrincipal Investigator

Alcon- C-10-083: A prospective, double-masked, active-controlled, single-dose randomized study to assess the safety, tolerability, and efficacy of ESBA 1008 versus Lucentis in adult patients with exudative age-related macular degeneration (AMD)
(2012)

Principal Investigator

iDEAL- 2010-007-03-DME: A randomized, multi-center, phase 2 study evaluating the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with laser photocoagulation or Ranibizumab in adult patients with Diabetic Macular Edema.
(2012)

Principal Investigator

Allergan REACH-AGN-150998: A phase 2, randomized, double-masked comparison of the effects and safety of treatment with AGN-150998 and ranibizumab on retinal edema and BCVA in treatment-naïve patients with exudative age-related macular degeneration (AMD).
(2012)

Ron P. Gallemore

Principal Investigator:

Allergan IST DME IIT-406: a randomized study to test the efficacy of Ozurdex versus Avastin on recalcitrant macular edema and macular function associated with diabetic retinopathy on patients with two or more prior intravitreal anti-VEGF drug injections.
(2012)

Principal Investigator

GSK- BAM114341: A phase 2, multi-center, randomized, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
(2012)

Principal Investigator

Novartis- CLFG316A2202: A multicenter, multiple dose study to assess the safety, tolerability, serum pharmacokinetics, and efficacy of intravitreal LFG316 in patients with neovascular age-related macular degeneration
(2012)

Principal Investigator

LUX Biosciences- LX-211-11: A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye
(2012)

Principal Investigator

Allergan BDP208397-001: A 12-Month, Multicenter, 2-Stage (Open Label, Dose Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
(2011)

Principal Investigator

Allergan- 1128277 – Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
(2011)

Ron P. Gallemore

Principal Investigator

Regeneron- VGFT-OD-1009: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (2011)

Principal Investigator

Novartis-CRFB002A2407: A 16-week evaluation of the novartis health management tool in assessing self-test visual function in patients with AMD treated with Lucentis (2011)

Principal Investigator

Santen: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye (2011)

Principal Investigator

Genentech-SHORE: A Multicenter, Randomized, Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion (2011)

Principal Investigator

Genentech- MAHALO: A Phase IB/II, Multicenter, Randomized, Single-Masked, Sham-Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy (2010)

Principal Investigator

Quan Nguyen READ3: Ranibizumab for Edema of the Macula in Diabetes; Protocol 3 with High Dose – the READ 3 study (2010)

Ron P. Gallemore

Principal Investigator

Regeneron: A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion
(2010)

Principal Investigator

Allergan: A 12-Month Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 ug Ozurdex as Adjunctive Therapy to Lucentis Compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration
(2010)

Principal Investigator

Valley Eye Retina PRESERVE: Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease
(2009)

Principal Investigator

Nevanac Ist, Ron Gallemore: Exploratory, Randomized, Controlled Clinical Study Assessing the Efficacy of Nepafenac as Adjunctive Therapy for Patients with Clinically Significant Diabetic Macular Edema
(2009)

Principal Investigator

Alcon ALKOR: C-07-43 - A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients
(2009)

Principal Investigator

Genentech HORIZON: An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) *or macular edema secondary to RETINAL VEIN OCCLUSION (RVO)* who have completed a genentech-sponsored RANIBIZUMAB STUDY
(2009)

Ron P. Gallemore

Principal Investigator

Genentech HARBOR: A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (2009)

Principal Investigator

Alcon GATE: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Denegeration (AMD) (2009)

Principal Investigator

Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (2008)

Principal Investigator

Lucentis IST, Ron Gallemore: Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular degeneration (2008)

Principal Investigator

QLT RADICAL BPDOCR 022: A Multicenter, Randomized, Single-Masked Study Comparing Reduced-fluence Visudyne – Lucentis Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD (2007)

Principal Investigator

Novartis Denali: A 24 Month Randomized, Double Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin (Visudyne) Photodynamic Therapy Administered in Conjunction with Ranibizumab (Lucentis) Versus Ranibizumab (Lucentis) Monotherapy in Patients with Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration. (2007)

Ron P. Gallemore

Principal Investigator

Genentech FVF4165g BRAVO: A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Vein Occlusion
(2007)

Principal Investigator

Genentech FVF4166g CRUISE: A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion
(2007)

Sub-Investigator

Othera Pharmaceuticals OT-551-C04 OMEGA: A Randomized, Double-Masked, Dose Ranging, Multicenter, Phase II Study Comparing the Safety and Efficacy of OT-551 with Placebo to Treat Geographic Atrophy Associated with Age-Related Macular Degeneration.
(2007)

Sub-Investigator

AREDS 2 (Age-Related Eye Disease Study 2): A Multi-Center, Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Age-Related Macular Degeneration
(2007)

Sub-Investigator

CNTF2: A Phase II Study of Implants on Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants with Visual Acuity Impairment Associates with Atrophic Macular Degeneration
(2007)

Sub-Investigator

CNTF3: A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants with Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome
(2007)

Ron P. Gallemore

Sub-Investigator

CNTF4: A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants with Retinitis Pigmentosa Using Visual Fields as the Primary Outcome (2007)

Sub-Investigator

Genentech SAILOR FVF3689g: A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). (2006)

Sub-Investigator

VISTA: A Randomized, Single-masked, Multicenter, Phase 2 Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (VISUDYNE Therapy) in Combination with Intravitreal Injection of Either 0 mg, 1 mg, or 4mg of Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne with Intravitreal Triamcinolone Acetonide (VisTA) Trial.

Sub-Investigator

Genentech FVF4168g RIDE: A Phase III, Double-Masked, Multi-Center, Randomized Sham Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (2007)

Sub-Investigator

TargeGen OPH-TG100801-002: An Open-Label Randomized, Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients with Choroidal Neovascularization Due to Age-Related Macular Degeneration (2007)

Sub-Investigator

Allergan SIRIUS 211745-001-00: A 2-Year, Multi-Center, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections of AGN211745 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (2007)

Ron P. Gallemore

Principal-Investigator

GenVec: Protocol #GV-003.001: An Open-Label, Phase I, Single Administration, Dose Escalation Study of Ad PEDF.11D in Neovascular Age-Related Macular Degeneration (AMD) and Protocol #GV000.000 Long-Term Follow Up Protocol for GenVec, Inc. Gene Transfer Product Candidates in Clinical Development

OTHER CLINICAL TRIALS

- *ISIS CS-7* "An open label study of the safety and efficacy of intravitreal ISIS 2922 in acquired immune deficiency syndrome patients with cytomegalovirus retinitis."
- *ISIS CS-9* "A randomized comparison of two dosage schedules of intravitreal ISIS 2922 for patients with advanced cytomegalovirus retinitis."
- *ProGancyclovir WV15376* "A randomized, controlled comparison of the safety and efficacy of RS-79070 an oral prodrug of gancyclovir, vs. IV gancyclovir as induction therapy for the treatment of newly diagnosed peripheral cytomegalovirus retinitis."
- *Roche ML 16356* "Open label safety study of Valganciclovir (RO 107-9070) in patients with CMV Retinitis and AIDS who have complications due to IV treatment."
- *Roche WV 15376* "A randomized, controlled comparison of the safety and efficacy of Valganciclovir vs. IV Ganciclovir as medication therapy for the treatment of newly diagnosed cytomegaloviruses."
- *Roche WV 15705* "An open label of the safety and tolerability of Valganciclovir, an oral prodrug of ganciclovir, for the treatment of cytomegalovirus retinitis in subjects with AIDS."
- *Pharmacia & Upjohn* "A phase III randomized, multi-center, double-masked, placebo controlled parallel group of in ethyl etiopurpurin (SnET2) photodynamic therapy in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration."
- *Alcon Research, LTD* "An evaluation of efficacy and safety of a sub-tenon's injection of anecortave acetate sterile suspension (60 mg/mL)

12

Ron P. Gallemore

versus placebo in patients with exudative AMD following treatment with photodynamic therapy using Visudyne."

- *QLT Pharmaceuticals BPD OCR 009* "A randomized, placebo-controlled, double-masked, multicenter, phase III study of the effect of Visudyne therapy in occult with no classic subfoveal CNV secondary to AMD."
- *QLT Pharmaceuticals BPD OCR 011* "A randomized, placebo controlled, double-masked, multicenter, phase II/III study of the effect of visudyne therapy in minimally classic subfoveal CNV secondary to AMD."
- *Oculex Pharmaceuticals, INC.* "A phase I/II randomized, double-masked, multicenter, dose-ranging, placebo controlled trial to assess the safety, tolerability and efficacy of DEX PS DDS in the treatment of inflammation following pars plana vitrectomy."
- *Advanced Corneal Systems, INC Protocol VIT-02-08961X* "Phase III safety and efficacy study of vitrase for ophthalmic intravitreal injection for clearance of severe vitreous hemorrhage."
- *Novartis Pharmaceuticals Corporation* "A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)."
- *Apheresis Technologies, Inc.* "A multicenter, prospective, randomized, double-masked study comparing the safety and efficacy of membrane differential filtration to a placebo treatment in patients with non-exudative age-related macular degeneration."
- *Eli Lilly and Company* Protein Kinase CB inhibitor—Diabetic Macular Edema Study (PKC-DMES)
- *Iris Medical Occult subfoveal choroidal neovascular membranes* "Transpupillary Thermotherapy of occult subfoveal choroidal neovascular membranes in Patients with Age-Related Macular Degeneration (The TTT4CNV Clinical Trial)."
- *Agouron Pharmaceuticals INC.* "A phase II, randomized, double-masked, placebo controlled study of the matrix metalloprotease inhibitor AB3340 in patients with subfoveal choroidal neovascularization associated with age related macular degeneration."

Ron P. Gallemore

- *ISTA Pharmaceuticals* "Phase III safety and efficacy study of Vitrase™ (Hyaluronidase) for ophthalmic intravitreal injection for clearance of severe vitreous hemorrhage."
- *Retina Vascular Surgery Branch Retinal Vein Occlusion Study* "The photocoagulation BRVO ST is designed to approach the anatomical lesion, arteriolar compression of a venule at the crossing site, by incising the vascular sheath-"sheathotomy." This study has used the guidelines of the original BRVO and enrolling patients whose eyes are ineligible for that study. Preliminary data suggest a rapid opening of the obstructed venule and re-establishment of the capillary bed blood flow with concomitant improvement in vision. Eligible patients are those with macular hemorrhage, chronic occlusions more than 180 days and eyes unresponsive to prior standard focal laser."
- *EyeTech Pharmaceuticals, Eye001* "A phase II/III randomized, single-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of Eye001 (anti-vegf pegylated aptamer) given at 6 weekly intervals for 54 weeks in patients with exudative age-related macular degeneration."

RESEARCH GRANTS

Duration	Position	Amount	Source and Title
1 Year 1997/1998	PI	\$2,500	Duke Eye Center Research Grant. "Application of differential display to identify genes expressed during retinal pigment epithelial cell proliferation".
1 Year 1997/1998	Co-PI	\$2,500	Duke Eye Center Research Grant, "Pharmacokinetics offluocinolone/5-fluoruracil release in the presence of intraocular gas tamponade"
1 Year 1995/1996	PI	\$15,000	Jules Stein Eye Institute Research Grant (Patricia Morrison Fund), "Ion channels and fluid transport in

Ron P. Gallemore

			human retinal pigment epithelium".
1 Year 1995/1996	PI	\$2,500	Research Grant, Alumni Association of the Jules Stein Eye Institute, "Video library of surgical ophthalmology"
1 Year 1994/1995	PI	\$15,000	Jules Stein Eye Institute Research Grant (Stella-Joseph Fund) "Ion transport pathways in human retinal pigment epithelium".
1 Year 1994/1995	PI	\$20,000	Stein-Oppenheimer Research Grant, University of California, Los Angeles, "Ion transport mechanisms in human retinal pigment epithelium".
2 Years 1992/1994	Co-PI	\$20,000	National Eye Institute R01 Research Grant "Ion transport in cultured human retinal pigment epithelium"
1 Year 1985/1986	PI	\$5,000	Retinitis Pigmentosa Foundation Research Grant "Ionic mechanisms of photoreceptor-retinal pigment epithelium responses"
1 Year 1985/1986	PI	\$2,500	Retinitis Pigmentosa Foundation Research Grant, "Anion transport mechanisms at the basolateral membrane of the retinal pigment epithelium"
Summer 1985	PI	\$1,200	Fight for Sight Student Fellowship, "Mechanisms of pH regulation in the avian retina"
1 Year 1994/1995	PI	\$1,000	President's Undergraduate Research Grant, U.C. Irvine, "Neutron activation analysis for determination of Uranium and Thorium"
1 Year	PI	\$1,000	

Ron P. Gallemore

1993/1994			President's Undergraduate Research Grant, U.C. Irvine, "Brain transplantation in the polyclad flatworm, <i>Notoplana acticola</i> "
1 Year 1981/1982	PI	\$5,000	Research Grant, Southern California Academy of Sciences, "Retinotectal and intertectal relay mechanisms in the frog visual system"

PEER REVIEWED PUBLICATIONS

1. **Gallemore, RP** and Fraser, SE (1982) *New insights into the function of the intertectal relay system of xenopus laevis.* J. So. Ca. Acad. Sci. : 1-20
2. **Gallemore, RP** and Fraser, SE (1983) *A possible function of the intertectal relay system in a primitive depth perception for xenopus laevis.* UCI J. Undergrad. Res. Bio. 13: 344-58.
3. **Gallemore, RP** and Koopowitz, H (1984) *Nerve repair and behavioral recovery following transplantation of the brain to the tail in notoplana acticola, a polyclad flatworm.* UCI J. Undergrad. Res. Bio. 14: 1-17
4. **Gallemore, RP**, Griff, ER and Steinberg, RH (1988) *Evidence in support of a photoreceptor origin for the "light-peak substance."* Invest. Ophthalmol Vis. Sci. 29: 566-571.
5. Nao-I N, Neilson, SE, **Gallemore, RP.** and Steinberg, RH (1989) *Effects of melatonin on the chick retinal pigment epithelium: membrane potentials and light-evoked responses.* Exp. Eye Res. 49: 1-17.
6. **Gallemore, RP**, and Steinberg, RH (1989) *Effects of DIDS on the chick retinal pigment epithelium: II mechanism of the light peak and other responses originating at the basal membrane.* J Neurosci 9: 1977-1984.

Ron P. Gallemore

7. **Gallemore, RP.** and Steinberg, RH (1989) *Effects of DIDS on the chick retinal pigment epithelium: I. Membrane potentials, apparent resistances and mechanisms.* J Neurosci. 9: 1968-1976.
8. Nao-I, **Gallemore, RP,** and Steinberg, RH (1990) *Effects of cAMP and IBMX on the chick retinal pigment epithelium: membrane potentials and light-evoked responses.* Invest. Ophthalmol. Vis. Sci. 31:54-66.
9. **Gallemore, RP** and Steinberg, RH (1990) *Effects of dopamine on the chick retinal pigment epithelium: Membrane potentials and light-evoked responses.* Invest. Ophthalmol. Vis. Sci. 31: 67-80
10. **Gallemore, RP** and Steinberg, RH (1991) *Cobalt increases photoreceptor-dependent responses of the chick retinal pigment epithelium.* Invest. Ophthalmol. Vis. Sci. 32:3041-3052.
11. Fujii, S, **Gallemore, RP.** Hughes, B and Steinberg, RH (1991) *Direct evidence for a basolateral membrane Cl conductance in toad retinal pigment epithelium.* Am. J. Physiol. 262:C374-C383.
12. **Gallemore, RP** (1992) *Ionic mechanism of the light-peak voltage of the DC Electroretinogram.* (Ph.D. Thesis) Univ. of California, San Francisco, San Francisco, CA
13. **Gallemore, RP,** Hernandez, E, Tayyanipour, R, Fujii, S and Steinberg, RH (1993) *Basolateral membrane Cl⁻ and K⁺ conductances in the dark-adapted chick retinal pigment epithelium.* J Neurophysiol. 70: 1656-1668
14. **Gallemore, RP** and Steinberg, RH (1993) *Light-evoked modulation of basal membrane CL⁻ conductance in chick retinal pigment epithelium: the light peak and fast oscillation.* J. Neurophysiol. 70: 1669-1680.
15. Hu, J, **Gallemore, RP,** Bok, D, Lee, AY, and Frambach, D (1994) *Localization of Na/ KATPase on cultured human retinal pigment epithelium.* Invest. Ophthalmol. Vis.Sci. 35(10): 3582-88.
16. Li, JD, **Gallemore, RP,** Dmitriev, AV, and Steinberg, RH (1994) *Light-Dependent hydration of the space surrounding photoreceptors in chick retina.* Invest. Ophthalmol. Vis. Sci. 35:2700-11.

17. **Gallemore, RP**, Li, J-D. Govardovskii, VJ and Steinberg, RH (1994) *Calcium gradients and light-evoked calcium changes outside rods in the intact cat retina.* Visual Neurosci 11:753-61.
18. **Gallemore, RP.** and Bokosky, J (1995) *Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: Modified technique allowing use of larger corneal grafts.* Cornea 14(1):33-38.
19. Hernandez, H, Hu J, Frambach, D and **Gallemore, RP.** (1995) ***Potassium Conductances in cultured bovine and human retinal pigment epithelium.*** Invest. Ophthalmol. Vis. Sci. 36:113-122.
20. Ju, J., **Gallemore, RP**, Bok, D and Frambach, D (1995) ***Chloride transport in Cultured fetal human retinal pigment epithelium.*** Exp. Eye Research 62:443-48
21. **Gallemore, RP**, Bokosky JE (1995) ***Penetrating keratoplasty with vitreoretinal surgery using the Eckardt temporary keratoprosthesis; modified technique allowing use of larger corneal grafts.*** Cornea. Jan; 14(1):33-8
22. Hernandez EV, Hu JG, Frambach DA, **Gallemore RP** (1995) ***Potassium conductances in cultured bovine and human retinal pigment epithelium.*** Invest. Ophthalmol Vis Sci. Jan; 36(1):113-22.
23. Jaffe GJ, Yang CS, Wang XC, Cousins SW, **Gallemore RP**, Ashton P. (1998) *Intravitreal sustained-release cyclosporine in the treatment of experimental Uveitis.* Ophthalmology. Jan;105(1):46-56.
24. **Gallemore RP**, Green J, Shorr N, Goldberg RA. (1999) Use of *isobutyl cyanoacrylate tissue adhesive to stabilize mucous membrane grafts in total socket reconstruction.* Ophthal Plast Reconstr Surg. May;15(3): 210-2.
25. Jumper JM, Machemer R, **Gallemore RP**, Jaffe GJ. (2000) *Exudative retinal detachment and retinitis associated with acquired syphilitic uveitis.* Retina. 20(2):190-4.

Ron P. Gallemore

26. **Gallemore RP**, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. (2000) *Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography.* Retina. 20(2):115-20.
27. Jumper JM, **Gallemore RP**, McCuen BW 2nd, Toth CA. (2000) *Features of macular hole closure in the early postoperative period using optical coherence tomography.* Retina. 20(3):232-7.
28. Perkins SL, **Gallemore RP**, Yang CH, Guo H, Ashton P, Jaffe GJ. (2000) *Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye.* Retina. 20(5):514-9.
29. **Gallemore RP**, Jumper M (2000) *Ins and Outs of Silicone Oil* Review of Ophthalmology 9/01/00
30. **Gallemore RP**, Boyer DS (2001) ***Retinal Detachment: The Best Treatment is Prevention*** Review of Ophthalmology. (4);121-1204/10/01
31. **Gallemore RP**, Boyer DS. (2002) **Save your sight. Eye disease and HIV.** Posit Living. 2001 Dec-2002 Jan;10(7):29-30.
32. Gallemore RP, Boyer DS (2002) Buckle, vit or bubble: RD management options. Review of Ophthalmology 9(04):4/15/02
33. **Gallemore RP**, Thomas EL, Boyer DS (2002) *Minimally Invasive Vitreoretinal Surgery* Review of Ophthalmology. 9(11): 11/19/02
34. Navas F, Boyer DS, Thomas EL, Novak RL, Chu TG, **Gallemore RP.** **Management of pupillary block glaucoma in phakic patients after vitrectomy with silicone oil injection.** Am J Ophthalmol. 2002 Oct;134(4):634-5.
35. Boyer DS, **Gallemore RP** *Clinical trials assess rheopheresis* Review of Ophthalmology 10(08):8/15/03
36. **Gallemore RP**, Boyer DS (2003) **AMD treatment update. Ophthalmology Management,** March 2003
37. Rajasekaran SA, Hu J, Gopal J, Gallemore R, Ryazantsev S, Bok D, Rajasekaran AK. **Na,K-ATPase inhibition alters tight junction**

Ron P. Gallemore

structure and permeability in human retinal pigment epithelial cells. Am J Physiol Cell Physiol. 2003 Jun;284(6):C1497-507.

38. Taban M, Thomas EL, Boyer DS, Novack RL, Chu TG, **Gallemore RP**. **Efficacy of verteporfin photodynamic therapy on laser-induced choroidal neovascularization and the ancillary effect on diabetic microvasculopathy.** Curr Eye Res. 2004 Apr;28(4):291-5.
39. Marmorstein AD, Rosenthal R, Stanton JB, Yocom J, Bakall B, Schiavone MT, Wadelius C, **Gallemore RP**, Marmorstein LY, Peachey NS, and Strauss O. (submitted).
40. Gallemore RP, Boyer DS (2004) Intravitreal Kenalog Injections. EyeNet, in press.

BOOK CHAPTERS AND REVIEWS

1. Miller, SS, Hughes, BA, and **Gallemore, RP**. Fluid transport in the retinal Pigment epithelium. Duane's Textbook of Clinical Ophthalmology. (*in prep*)
2. Hughes, BA, **Gallemore, RP** and Miller, SS. Ion transport mechanisms in the retinal pigment epithelium. In: J Dowling, ed Physiological Reviews. (*in prep*)
3. **Gallemore, RP**, and Goldberg, RA (1996) Videotape library of surgical ophthalmology. Jules Stein Eye Institute, UCLA Medical Center.
4. **Gallemore RP**, Hughes BA and Miller SS (1997) Retinal pigment epithelial Transport and its relationship to the electroretinogram. In: N. Osborne and G. Chader, eds. Progress in Retinal and Eye Research.
5. Hughes, BA, **Gallemore, RP** and Miller, SS (1998) Transport mechanisms in the retinal pigment epithelium. In: The retinal pigment epithelium: function and disease. Marmor MF, Wolfensberger TJ, editors. New York: Oxford University Press; p. 103-34.
6. **Gallemore, RP**, Maruiwa, F and Marmor MF (1998) Clinical electrophysiology of the retinal pigment epithelium. In: M.F. Marmor and T. J. Wolfensberger, eds. The Retinal Pigment Epithelium: Function and Disease.

Ron P. Gallemore

7. **Gallemore RP**, Hughes BA and Miller SS (1998) Light-induced responses of the Retinal pigment epithelium. In: M.F. Marmor and T. J. Wolfensberger, eds. The Retinal Pigment Epithelium: Function and Disease.
8. **Gallemore RP**, McCuen B II. (2000) **Silicone oil tamponade in Vitreoretinal surgery**. In: S. Ryan ed., Retina, Chapter 127.
9. **Gallemore RP**. (2000) Treatment update: Dry Macular Degeneration. Macular Degeneration Partnership Web Site Review, 06/01/00 (www.amd.org)
10. **Gallemore RP**. (2000) Treatment update: Wet Macular Degeneration. Macular Degeneration Partnership Web Site Review, 07/01/00 (www.amd.org)
11. Gallemore RP. (2000) **Ask the doctor: macular degeneration**. Macular Degeneration Partnership Web Site Review, 06/01/00 (www.amd.org)
12. **Gallemore RP**, Boyer DS (2003) **Nutrition and the retina**. Macular Degeneration Partnership Web Site Review, 03/01/03 (www.amd.org)
13. **Gallemore RP**, Kaiser P, Han D. (2003) Article review: **Hypertensive retinopathy more common in blacks**. Review of Ophthalmology, 10(05):5/15/03
14. **Gallemore RP**, Kaiser P, Han D. **Insulin Lispro Benefits Pregnant Women with Diabetic Retinopathy**. Review of Ophthalmology, 10(05):5/15/03
15. **Gallemore RP** (2003) **Product review: Macular degeneration supplement**. Ophthalmology Management, June 2003
16. **Gallemore RP** (2004) Product review: **Supplement for optic nerve health**. Ophthalmology Management, January 2004.
17. **Gallemore RP**, McCuen B II. (2005) **Silicone oil tamponade in vitreoretinal surgery**. In: Ryan S, ed., Retina. (in prep.)

PRESENTATIONS / ABSTRACTS

1. **Gallemore, RP**, Calvin Chou, and Madeline Eells (2010) Monthly Versus Prn Ranibizumab for Neovascular Age-related Macular Degeneration: a Randomized Phase 2 Open-label Study Using High Resolution OCT (ASRS)
2. **Gallemore, RP**, Calvin Chou, and David Nguyen (2010) Nucleoside Analogue Reverse Transcriptase Inhibitor- induced Retinal Degeneration in HIV-positive patient resembles Gyrate Atrophy (ASRS)

Ron P. Gallemore

3. Steinberg, RH, **Gallemore, RP**, and Griff, E (1987) Origin of the light peak: Contribution from the neutral retina. Invest. Ophthalmol. Vis Sci (ARVO)28: 402.
4. **Gallemore, RP**. and Steinberg, RH (1987) Effects of the putative anion Transport inhibitor DIDS on the RPE basal membrane and the c-wave. Invest. Ophthalmol. Vis. Sci. (ARVO) 28: 382.
5. **Gallemore, RP**, and Steinberg RH (1987) Effects of cobalt and low calcium on light-evoked (K^+) changes in the sub retinal space and on the chick dc electroretinogram. Soc. Neurosci. Abstr. 13: 1049.
6. Steinberg, RH and **Gallemore, RP**. (1988) Effects of dopamine on RPE membrane Potentials and light-evoked responses in chick. Invest. Ophthalmol. Vis. Sci.(ARVO) 29: 100.
7. Nao-I, N, **Gallemore, RP**. and Steinberg, RH (1988) Effects of camp on RPEMembrane potentials and Light-evoked responses in chick. Invest. Ophthalmol. Vis. Sci. (ARVO) 29:100
8. **Gallemore, RP**, and Steinberg, RH (1988) Light-evoked changes in (Ca^{2+}). In chick Retina. Invest. Ophthalmol. Vis. Sci. ARVO) 29: 103.
9. **Gallemore, RP**, and Steinberg, RH (1988) Evidence for a Cl^- conductance in Chick-retinal pigment epithelium that may contribute to responses originating at the basal membrane. Soc. Neurosci. Abstr 14:357.
10. **Gallemore, RP**, Yamamoto, F, Steinberg, RH (1990) (Ca^{2+}). Gradients and light-evoked (Ca^{2+}). Changes in cat retina, in vivo. Soc. Neurosci. Abstr. 16:714.
11. Fujii, S, **Gallemore, RP**. Hughes, B. and Steinberg, R.H. (1990) Evidence for a basolateral membrane Cl^- conductance in toad retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO) 31: 388.
12. Ng, C., **Gallemore, RP**. and Steinberg, R.H. (1991) The Cl^- transport inhibitor, furosemide, selectively blocks light-evoked responses of the chick retinal pigment epithelium basal membrane. Clinical Res. 39: 128A.

Ron P. Gallemore

13. Li, J.D., **Gallemore, RP.** And Steinberg, R. H. (1991) Effects of systemic hypoxia on $(Ca^{2+})_o$ in the intact cat retina. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 32:837.
14. Hernandez, E., **Gallemore, RP.** Tayyanipour, R., Fujii, S., and Steinberg, R.H., (1991) Basal membrane Cl^- and K^+ conductances in chick retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 32:837.
15. **Gallemore, RP.** and Steinberg, R.H. (1991) The light peak of the DC ERG is associated with an increase in Cl^- conductance in chick RPE. Invest. Ophthalmol. Vis. Sci. (ARVO aster) 32: 837.
16. Li, J.D., **Gallemore, RP.** and Steinberg, R.H. (1992) Light induced increase in Subretinal space volume in chick retina. Invest. Ophthalmol. Vis. Sci. (ARVO aster) 33:913.
17. Hu, J., Lee, A.Y., Bok, D., **Gallemore, RP.** and Frambach, D. (1993) Electrophysiological localization of Na/K ATPase on confluent monolayers of cultured human RPE. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 34: 1445.
18. Hernandez, E., Frambach, D. A., Bok, D., Farber, D. and **Gallemore, RP.** (1993) Apical and basolateral membrane potassium conductances in cultured monolayers of fetal bovine and human RPE. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 34: 873.
19. Bokosky, J., **Gallemore, RP.** Mani, H., Poliner, L., Smith, M., Bitner, D., Lipton, B. and Robinson, F. (1993) Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: A modified technique allowing use of larger corneal grafts. Cornea (Supplement, Eye Bank Assoc. Meeting, San Diego, CA, June 1993).
20. **Gallemore, RP.** and Bokosky, J. (1993) Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: Modified technique allowing use of larger corneal grafts. (Supplement, Eye Bank Assoc. Meeting, Chicago, Nov. 1993).
21. **Gallemore, RP.** Judge, A. and Hoft, R. (1994) A case of fungal keratitis caused by *Chaetomium*. Ocular Micro. Immune. Group, San Francisco, CA

Ron P. Gallemore

22. **Gallemore, RP.** Hernandez, E.V., and Steinberg, R.H. (1994) Choroid-free preparation of explant retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci (ARVO Abstr.) 35: 1761.
23. Hu, J. G., Bok, D., Frambach, D.A. and **Gallemore, RP.** (1995) Beta-adrenergic receptors activate basal membrane ion channels in cultured fetal human RPE. Invest. Ophthalmol. Vis. Sci. (ARVO Abstr) 36: S587.
24. **Gallemore, RP.** Hu, H.G., Frambach, D.A. and Bok, D. (1995) Ion transport pathways in cultured human retinal pigment epithelium. Fifth Biennial Schepens International Society Meeting. Mexico City, Mexico.
25. **Gallemore, RP.** Hu, J.G., Frambach, D.A. and Bok, D (1995) Ion transport in cultured human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci (ARVO Abstr) 36: S216.
26. Hu, J., **Gallemore, RP.** Maruiwa, F. and Bok, B. (1996) Retinal potassium modulates multiple ion transport mechanisms in cultured human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci (ARVO Abstr.) 37: S229.
27. Maruiwa, F., **Gallemore, RP,** Takahira, M., Hughes, B., Hu, J. and Bok, B (1996) Membrane polarization of potassium conductances in cultured human retinal pigment epithelium Invest. Ophthalmol. Vis. Sci (ARVO Abstr) 36: S229.
28. Maruiwa, F., **Gallemore, RP.** Hu, J. and Bok, B. (1997) Nonsteroidal anti-inflammatory drugs (NSAIDS) modulate chloride channels in human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 38: S467.
29. Chen, J., Duker, J., Kim, V., **Gallemore, RP.** Jaffe, G. J., and Ashton, P. (1997) A 1.5 year gancyclovir implant for CMV retinitis. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38: S1103.
30. Wang, X. C., Yang, D. C. S., Cousin, S.W., **Gallemore, RP.** Ashton, P. and Jaffe, G.J. (1997) Intravitreal sustained release cyclosporine A (CsA) in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 38: S211.

Ron P. Gallemore

31. Yang, C.C., **Gallemore, RP**, Niccolo, M., Kasahara, N., Ashton, P. and Jaffe, G. J. (1997) Retinoic acid (RA) intravitreal implants for the treatment of experimental proliferative vitreoretinopathy (PVR)- pharmacokinetics and ocular toxicity. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38:211.
32. **Gallemore, RP**, Yang, C.C., Guo, H., Cynkowschi, T., Synkowska, G., Ashton, P. and Jaffe, G. J. (1997) Inhibition of proliferative vitreoretinopathy (PVR) using a fluocinolone/5-fluorouracil sustained release pellet. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38: S211.
33. Toth CA, **Gallemore RP**, Jumper JM. (1997) APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY (OCT) IN SURGICAL MANAGEMENT OF MACULAR DISEASE. Vitreous Society Meeting.
34. Gallemore RP, Thomas EL (2000) **High Definition Video of High Speed Indentation Delamination**. American Acad, Ophthal., Dallas.
33. Boyer, Ds, **Gallemore, RP**, (March 2007) "Changing Approaches to Diabetic Retinopathy", Review of Ophthalmology/pages 88 – 92.

NEWSLETTER ARTICLES AND BRIEF REVIEWS

Gallemore, RP (May/June 2000) "Treatment Update: Dry Macular Degeneration" *The Observer*

Gallemore, RP (Winter 2000) "Dry Macular Degeneration" *The Observer*

Gallemore, RP (October V2, Issue 1) "Gallemore's Corner: Not Diabetes Again! Treatment Update II Clinical Studies" *The Open Angle*

Gallemore, RP (Spring 2000) "Millennium Treatments: Wet Macular Degeneration" *Scene*

Gallemore, RP (Summer 2000) "Millennium Treatments: Dry Macular Degeneration" *Scene*

Gallemore, RP (Summer 2000) "Management Strategies for Retinal Detachment After Cataract Surgery" *Ocular Surgery News*

Gallemore, RP (Spring 2001) "The Peripheral Retina: What to Look for and When to Refer" *The Observer, The Open Angle*

Ron P. Gallemore

Gallemore, RP (Summer 2001) "Pre-Operative Evaluation of the LASIK Patient: The Retina Perspective" *The Observer, The Open Angle*

Gallemore, RP (Fall 2001) "Retinal Vein Occlusions: Make the Diagnosis" *The Observer, The Open Angle*

Gallemore, RP (Winter 2001) "Retinal Vein Occlusions: Treatment Update" *The Observer, The Open Angle*

Gallemore RP, Boyer DS (Summer 2002) **White Dots and Blind Spots: Part 1** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Fall 2002) **White Dots and Blind Spots: Part 2** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Winter 2002) **Nutrition and the Retina: What should we tell out patients?** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Spring 2003) **Wolfberry and more: What other antioxidants may help our patients?** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Summer 2003) **AMD treatments in the pipeline** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Fall 2003) **Intravitreal Kenalog injections: A "cure-all" for macular disease?** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Winter 2003) **Toxic Maculopathies: A Responsibility to Screen** (Observer, The Open Angle)

Gallemore RP, Boyer DS (Spring 2004) **Optic Neuropathies with Disc Edema: Differential Diagnosis and Management** (Observer, The Open Angle)

Gallemore RP (August 2004) *Wet macular degeneration: clinical research update.* *The Open Angle, The Observer*

Gallemore RP, Boyer DS (Summer 2004) Clinical Research Update: Wet Macular Degeneration, Observer, The Open Angle, and The Rio Hondo Optometric Society Clinical Update

Ron P. Gallemore

MANUSCRIPTS IN PREPARATION

- **Gallemore, RP**, Hu, J, Hughes, B, Takahira, M and Bok, B. Beta 2 adrenergic receptors activate cyclic AMP-dependent chloride channels in cultured human retinal pigment epithelium *in prep for* Am. J. Physiol.
- **Gallemore, RP**, Judge, A., and Hoft, R. A case of fungal keratitis caused by *Chaetomium* in prep. *Cornea*
- Maruiwa, F, **Gallemore, RP**, Hu, J, Hughes, B, Takahira, M and Bok, B. Membrane polarization of potassium channel subtypes in human retinal pigment epithelium. *in prep for* Invest. Ophthalmol. Vis. Sci.
- **Gallemore, RP**, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Nonsteroidal anti-inflammatory drugs modulate Cl channels in human retinal pigment epithelium *in prep. for* Invest. Ophthalmol. Vis. Sci.
- **Gallemore, RP**, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Purinergic type 2 receptors modulate Cl and K channels in human retinal pigment epithelium. *in prep. for* Invest. Ophthalmol. Vis. Sci.
- Maruiwa, F, **Gallemore, RP**, Hu, J. and Bok, B. Electrogenic H_2CO_3 cotransport in human retinal pigment epithelium. *in prep. for* Invest. Ophthalmol. Vis. Sci.
- Maruiwa, F, **Gallemore, RP**, Hu, J. and Bok, B. Electrophysiological effects of transepithelial osmotic gradients in human retinal pigment epithelium *in prep. for* Exp Eye Res.
- **Gallemore, RP**, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Swelling activated chloride channels in human retinal pigment epithelium *in prep for* Am. J. Physiol.
- DCS, Yang, Wang W-C, Cousin SW, **Gallemore, RP**, Ashton, P, and Jaffe, GJ. Intravitreal sustained release cyclosporine A (CsA) in the treatment of experimental uveitis *in prep for* Invest. Ophthalmol. Vis. Sci.
- **Gallemore, RP**, Maruiwa, F, Heckenlively, J, Lewis, R, Sidikaro, Y. Lacunar loss of choriocapillaris in select retinal dystrophies *in prep for* Survey of Ophthalmol

Ron P. Gallemore

- **Gallemore, RP**, Yang, CC, Guo, H, Cynkowshi, T, Synkowska, G, Ashton, P. and Jaffe, G. J. Inhibition of proliferative vitreoretinopathy (PVR) using sustained-release intravitreal fluocinolone/5-fluoruracil co-drug *in prep for Invest. Ophthalmol Vis. Sci.*
- **Gallemore, RP**, Jumper, JM, and Toth, C, Application of ocular coherence tomography in the diagnosis and management of macular disease (*in prep*)
- **Gallemore, RP**, and Toth, C. Role for Vitreoretinal structure in the pathogenesis of senile retinosis in prep for Am. J. Ophthalmol.

RESEARCH PROJECTS

- **Gallemore, RP**, Roberts, W, and Jaffe, G. Application of differential display to identify genes expressed during retinal pigment epithelial cell proliferation. (Advisor: Dr. Glenn Jaffe)
- **Gallemore, RP**, Jumper, J.M., and McCuen, B.W. II Axial length measurements with silicone oil tamponade. (Advisor: Dr. Brooks McCuen II)
- Perkins, S, **Gallemore, RP**, Yang, C.C. and Jaffe, G. Pharmacokinetics of fluocinolone/5-fluoruracil release in the presence of intraocular gas tamponade. (Advisor: Dr. Glenn Jaffe.)
- Yang, CC, **Gallemore, RP**, Niccolo, M, Kasahara, N, Ashton, P and Jaffe, GJ. Retinoic acid (RA) intravitreal implants for the treatment of experimental proliferative vitreoretinopathy (PVR) (Advisor: Dr. Glenn Jaffe)
- Chen, J, Duker, J, Kim, V, **Gallemore, RP**, Jaffe, GJ and Ashton, P. A 1.5 year gancyclovir implant for CMV retinitis. (Advisor: Dr. Glenn Jaffe)
- **Gallemore, RP**, and Toth, C. Application of ocular coherence tomography for the diagnosis and management of macular disease. (Advisor: Dr. Cynthia Toth)
- Steuer, E. and **Gallemore, RP**. Novel methodologies for mammalian retinal pigment epithelium culture and transplantation. (Advisor: Dr. Glenn J. Jaffe)

Ron P. Gallemore

American Academy of Ophthalmology Course Instructor

2001-2003	Mccuen B, Jumper LM, Gallemore RP. Silicone Oil in Vitreoretinal Surgery. American Acad, Ophthal.
2003-2006	Proliferative Vitreoretinopathy
2000	Gallemore, RP, Thomas EL. High Definition Video of High Speed Indentation Delamination. American Acad, Ophthal., Dallas

SELECTED LECTURES

1982 - 1983	"What the frogs eye tells the frogs brain." Student Speaker's Forum Community Lecture Series, University of California, Irvine.
1984 - 1985	"From heads to tails: Brain transplantation in the polyclad flatworm" Student Speaker's Forum Community Lecture Series, University of California, Irvine.
1985 - 1986	"How the eye sees: Insights from the electroretinogram." Student Speakers Forum Community Lecture Series, University of California, Irvine.
07/88	"Glucose control and amyloid proteins." Program in Biological Sciences Lecture Series, University of California, San Francisco.
05/89	"Neuronal mechanisms of rheumatoid arthritis." Program in Biological Sciences Lecture Series, University of California, San Francisco.
05/93	"Bechet's disease associated with aseptic meningitis." Rounds Lecture, Mercy Hospital and Medical Center, San Diego, CA
07/93	"Hyphema Management" Rounds Lecture, UCLA Harbor Hospital, Torrance, CA

Ron P. Gallemore

- 07/93 "Ocular trauma: The ruptured globe." Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA
- 08/93 "Oculoplastics and trauma" Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA
- 09/93 "Pterygium Surgery" Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA
- 12/93 "Pahtologic myopia" Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 02/94 "Age -related extra macular disciform degeneration" Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 03/94 "Fungal keratitis." Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 05/94 "Ion Transport in Cultured Human RPE" Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA
- 10/94 "Painless proptosis." Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 10/94 "Penetrating keratoplasty with Vitreoretinal surgery utilizing temporary keratoprostheses: modified techniques allowing use of larger corneal grafts." Ocular Microbiology and Immunology Group, Chicago, IL.
- 04/95 "Posterior polymorphous dystrophy." Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 05/95 "Laser retinopexy of peripheral retinal lesions." Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA.

Ron P. Gallemore

- 05/95 "Fluid transport and ion channels in human retinal pigment epithelium." Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA
- 08/95 "Physiology and pathophysiology of the foveal avascular zone." Basic Science Lecture Series, Grand Rounds, Jules Stein Eye Institute, Los Angeles, CA
- 09/95 "The DC Electroretinogram: Its Discovery and Significance." Roy H. Steinberg, M.D., PhD., Festschrift Celebration, U.C. San Francisco
- 01/96 "Acute vision loss associated with intranasal cocaine abuse" Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 03/96 "Acute retinal necrosis syndrome." Basic Science Lecture Series, Grand Rounds, Jules Stein Eye Institute, Los Angeles, CA
- 04/96 "Management of suprachoroidal hemorrhage." Retina Rounds Resident Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 05/96 "Ochronosis oculi" Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA
- 05/96 "Volume sensitive chloride channels in human retinal pigment epithelium: physiology and clinical significance." Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA
- 08/97 "Retinal pigment epithelium function in normal and disease states". Visiting Lecturer, Department of Molecular and Cell Biology, Scripps Clinics and Research Center, San Diego, CA
- 10/97 "Intravitreal drug delivery for posterior segment disease." Visiting Lecturer, Department of Ophthalmology, Cleveland Clinic Foundation Cleveland, OH

Ron P. Gallemore

- 03/14/98 "Retinal transplantation." Retina Update 1998, Good Samaritan Hospital, Los Angeles, CA
- 03/14/98 "Intravitreal drug delivery for posterior segment disease." Retina Update 1998, Good Samaritan Hospital, Los Angeles, CA
- 05/12/98 "Water and Ion Transport by the Retinal Pigment Epithelium," Symposium: "IPE Transplantation: Theoretical and Practical Considerations," Fort Lauderdale, FL
- 09/98 "Diagnosis and Management of Ocular Emergencies." California Medical Center, Los Angeles, CA
- 10/01/98 "Common Eye Emergencies" Grand Rounds Lecture, Santa Marta Hospital, Los Angeles, CA
- 11/08/98 "Ophthalmic Manifestation of Systemic Disease in the Pediatric Patient." Pediatric Grand Rounds, White Memorial Medical Center, Los Angeles, CA.
- 11/12/98 "AIDS Related Retinopathies." Grand Rounds Lecture, Good Samaritan Hospital, Los Angeles, CA
- 11/19/98 "Ocular Emergencies." Grand Rounds Lecture, White Memorial Medical Center, Los Angeles, CA
- 12/02/98 "The eye in systemic disease." Grand Rounds Lecture, Cedars Sinai Medical Center, Beverly Hills, CA
- 01/04/99 "Diabetic Retinopathy." Endocrine Grand Rounds, Cedars Sinai Medical Center, Beverly Hills, CA
- 03/12/99 "Diagnosis and Management of Ocular Trauma." Grand Rounds Lecture, Northridge Hospital Medical Center, Northridge, CA
- 03/18/99 "Overview of current research studies on macular degeneration." Braille Institute Lecture, Pacific Inn, Torrance, CA

Ron P. Gallemore

- 03/20/99 "Future of Vitreoretinal management." Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA
- 03/20/99 "Panoramic viewing for Vitreoretinal surgery." Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA
- 03/20/99 "Subretinal surgery." Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA
- 03/10/00 "OCT in Macular Disease," Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA
- 03/10/00 "Sub-Macular Surgery," Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA
- 03/10/00 "Surgical Management of Proliferative Diabetic Retinopathy," Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA
- 03/10/00 "Future Advances in Vitreo-Retinal Surgery," Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA
- 09/26/00 "Treatment Update: Diabetic Retinopathy," Endocrinology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA
- 10/22/00 "Silicone Oil and Vitreo-Retinal Surgery," AAO
- 11/12/00 "Mac Degeneration & Diabetic Retinopathy," California Optometric Association, Academy Meeting, Monterey, CA
- 12/5/00 'Treatment Update: Macular Degeneration', Braille Institute, Los Angeles, CA
- 05/17/01 "Overview of current research studies on retinal diseases". Braille Institute, Los Angeles, CA

Ron P. Gallemore

- 05/17/01 "Update on Macular Diseases," South Bay Optometric Society Meeting, Torrance, CA
- 05/18/01 "Update on Diabetic Retinopathy and Advances in Macular Degeneration Therapy," Rio Hondo Optometric Society Annual In vocational meeting, Cerritos, CA
- 06/25/01 "Macular Degeneration," Braille Institute, Los Angeles, CA
- 08/17/01 "Common Eye Emergencies," "Ocular Manifestations of Systemic Disease," "Treatment update: Macular Degeneration and Diabetic Retinopathy," Invited Lecturer, Rio Hondo Optometric Society, Las Vegas, NV
- 03/16/02 "Surgical Management of AMD" Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA
- 03/16/02 "OCT for Diagnosis for Retinal Disease" Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA
- 03/16/02 "OCT Management of Complex Vitreoretinal Diseases" Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA
- 03/16/02 "The Future of V-R Management" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA
- 05/08/02 "Seminar on Macular Degeneration and low vision rehabilitation" Braille Institute, Los Angeles, CA.
- 03/22/03 "Surgical Management of Macular Degeneration" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA
- 03/22/03 "Surgical and Laser Shunting Procedures for Venous Occlusive Diseases" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

Ron P. Gallemore

- 03/22/03 "OCT Management of Complex Vitreoretinal Diseases" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA
- 03/22/03 "Surgical Management of Diabetic Retinopathy" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA
- 03/22/03 "The Future of Vitreoretinal Management" Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA
- 03/22/03 "Surgical Management of Diabetic Retinopathy" Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA
- 03/22/03 "Surgical Management of Diabetic Retinopathy" Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA
- 04/16/03 "Optical coherence tomography for diagnosis and treatment of macular disease," South Bay Optometric Society Annual In vocational Meeting, Guest Lecturer, Torrance, CA
- 05/24/03 Retina Review, Ophthalmology Assessment Program Preparatory Course, Cedars Sinai Medical Center, Los Angeles, CA
- 06/16/03 "*Overview of the latest research on macular degeneration*" Oasis Center and the Braille Institute, Los Angeles, CA.
- 08/23/03 "*Rheopheresis and other novel treatments for macular diseases,*" Rio Hondo Optometric Society Clinical Update, Las Vegas, NV
- 11/22/03 "Clinical trials for macular degeneration" Macular Degeneration Research Foundation, Skirball Cultural Center, Los Angeles, CA.

Ron P. Gallemore

- 02/12/04 "The Latest Research on Macular Degeneration," Braille Institute, Los Angeles, CA.
- 03/20/04 "Surgical Management of Macular Degeneration" Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA
- 03/20/04 "OCT Management of Complex Vitreoretinal Diseases," Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA
- 03/20/04 "Surgical Management of Diabetic Retinopathy," Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA
- 03/20/04 "Progressive pigmented lesion of the macula," Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA
- 03/20/04 "The Future of Vitreoretinal Management: Clinical Trials Update" Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA
- 05/22/04 Retina Review, Ophthalmology Assessment Program Preparatory Course, Cedars Sinai Medical Center, Los Angeles, CA
- 06/16/04 Retina Update: "Intravitreal Kenalog: A cure all for macular diseases?", San Bernardino County Optometric Society Meeting, Ontario, CA
- 06/26/04 "Intravitreal Kenalog injections for management of macular diseases." Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV
- 06/26/04 "Rheopheresis and other novel treatments for macular disease." Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV

Ron P. Gallemore

- 06/26/04 "Differential Diagnosis of Macular Diseases." Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV
- 07/31/04 "Intravitreal Kenalog Injections: A "cure all" for macular diseases?" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/31/04 "AMD and beyond: Differential diagnosis of macular diseases" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/31/04 "Treatment Update: Macular degeneration" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/31/04 "Treatment Update: Diabetic Retinopathy" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/31/04 "Immunologic disorders and retinal disease" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/31/04 "Optical coherence tomography (OCT) for diagnosis and management of macular diseases" Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile
- 07/25/10 "Retinal Unknowns", Knott's Berry Farm Resort Hotel, Buena Park, California
- 07/25/10 "Ocular Inflammation vs. Infection: How to Differentiate and Prevent", Knott's Berry Farm Resort Hotel, Buena Park, California
- 07/24/11 "Retinal Update: New Surgical and Treatment Options for Retinal Disease", Rio Hondo, Yorba Linda, California

Ron P. Gallemore

- | | |
|----------|--|
| 10/13/11 | "New Treatment Options for Retinal Diseases: What You and Your Patients Need to Know", Annual Symposium, Torrance, California |
| 10/13/11 | "Different Diagnoses of Neuroretinopathies", Annual Symposium, Torrance, California |
| 10/13/11 | "Improving Outcomes for Your Cataract and Refractive Surgery Patients with Retinal Disease", Annual Symposium, Torrance, California |
| 07/22/12 | "New Treatments and Surgical Options for Retinal Disease: What You and Your Patients Need to Know", Rio Hondo, Yorba Linda, California |

SCIENTIFIC REVIEWER

Retina
Investigative Ophthalmology and Visual Science
American Journal of Ophthalmology
British Journal of Ophthalmology
Review of Ophthalmology

**SOCIETY MEMBERSHIPS
AND ORGANIZATIONS**

American Academy of Ophthalmology
American Society of Retina Specialists
American Academy for the Advancement of Science
American Medical Association
Association for Research in Vision and Ophthalmology
Braille Institute
Good Samaritan Hospital Continuing Medical Education Board
Discovery Fund, Cedars-Sinai Medical Center, Los Angeles, CA

Ron P. Gallemore

Macular Degeneration Foundation, Board of
Scientific Advisors

Los Angeles County Medical Association

Society for Neuroscience

Society of Heeds Fellows

Ron Michaels Society (of Retinal Specialists)

Eye Care America of the AAO